Secondary Logo

Share this article on:

Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring

Balkus, Jennifer, E., PhD, MPH*,†,‡; Brown, Elizabeth, R., ScD*,§; Palanee-Phillips, Thesla, PhD; Matovu Kiweewa, Flavia, MBChB; Mgodi, Nyaradzo, MBChC, Mmed**; Naidoo, Logashvari, MBChB††; Mbilizi, Yamikani, MBBS‡‡; Jeenarain, Nitesha, BPharm††; Gaffoor, Zakir, MMedSci††; Siva, Samantha, MMedSci††; Nair, Gonasangrie, MBChB§§; Pather, Arendevi, BPharm††; Baeten, Jared, M., MD, PhD†,‡,¶¶

JAIDS Journal of Acquired Immune Deficiency Syndromes: January 1, 2018 - Volume 77 - Issue 1 - p e8–e10
doi: 10.1097/QAI.0000000000001556
Letters to the Editor

*Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA

Departments of Global Health

Epidemiology

§Biostatistics, University of Washington, Seattle, WA

Wits Reproductive Health and HIV Institute, Johannesburg, South Africa

Makerere University, Johns Hopkins University Research Collaboration, Kampala, Uganda

**University of Zimbabwe, Harare, Zimbabwe

††South African Medical Research Council, Durban, South Africa

‡‡Medical College of Malawi—Johns Hopkins University Research Collaboration, Blantyre, Malawi

§§Emavundleni Research Centre, Cape Town, South Africa

¶¶Department of Medicine, University of Washington, Seattle, WA

This research was funded in part by a grant from the U.S. National Institutes of Health (NIH) (R03MH106352) and a 2014 developmental grant from the University of Washington Center for AIDS Research (CFAR), an NIH-funded program under award number P30AI027757, which is supported by the following NIH Institutes and Centers (NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA, NIGMS, and NIDDK). The Microbicide Trials Network (MTN) is funded by NIAID (UM1AI068633, UM1AI068615, and UM1AI106707), with co-funding from NICHD and NIMH, all components of the NIH.

Presented in part at the HIV Research for Prevention Conference; October 17–20, 2016; Chicago, IL.

The authors have no conflicts of interest to disclose.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

To the Editors:

Young women living in Eastern and Southern Africa continue to be at high risk of acquiring HIV-1, highlighting the urgent need for access to effective HIV-1 prevention interventions.1 Recent World Health Organization guidelines recommend that daily oral pre-exposure prophylaxis (PrEP) be offered as a priority prevention intervention for populations with an HIV-1 incidence of approximately 3% per year or higher.2 However, it is difficult to prospectively identify individuals who may be considered part of such populations, especially in generalized epidemics where risk may be heterogeneous, despite a high background HIV-1 prevalence. Empiric HIV risk assessment tools have been developed for several groups, including African heterosexual HIV-1 serodiscordant couples3 and men who have sex with men in the United States,4,5 in an attempt to discern those at the highest risk within these populations. These tools have been used in PrEP demonstration projects and as part of national guidelines to help guide PrEP implementation efforts.6 To attempt to identify women at higher risk of HIV-1 acquisition, we developed and validated a risk score using data from women who participated in several HIV-1 prevention trials.7 The score was derived from women who participated in MTN 003/VOICE, a phase IIB safety and effectiveness trial of oral and vaginal tenofovir-based PrEP.8 The VOICE risk score showed modest performance in identifying women at the highest risk of HIV-1 acquisition over the course of 1 year and having a risk score ≥3 correlated with an HIV-1 incidence of >3% per year. The VOICE risk score may represent a valuable tool to assist with targeted PrEP delivery in countries, such as South Africa and Kenya, that are in the process of scaling-up access to PrEP.9 However, further validation of the risk score is important for understanding the tool's performance when applied to different populations of women at risk of HIV-1 in these regions.

To further assess the VOICE risk score performance, we used data from women enrolled in MTN-020/ASPIRE, a randomized, double-blind, placebo-controlled, phase III trial of the safety and effectiveness of the dapivirine vaginal ring for HIV-1 prevention (Clinicaltrials.gov NCT01617096). Detailed methods and results for the trial have been published.10 Briefly, healthy, sexually active, HIV-1 uninfected women aged 18–45 years from Malawi, South Africa, Uganda, and Zimbabwe were enrolled and were tested monthly for HIV-1 using rapid antibody tests for a minimum of 1 year. Participants provided written informed consent, and applicable local and national ethical and regulatory authorities approved the study protocol.

The risk score was applied to data collected from ASPIRE participants at enrollment. The VOICE risk score is calculated based on taking the sum of the point values that correspond to the following factors assessed at enrollment: age <25 years = 2 points; unmarried or not living with partner = 2 points; partner does not provide financial or material support = 1 point; primary partner has other partners (yes or do not know) = 2 points; alcohol use in the past 3 months = 1 point; having a curable sexually transmitted infection (STI) at baseline = 1 point; herpes simplex virus type 2 status = 2 points. In ASPIRE, data were not collected on living with primary partner, partner provides financial support, or herpes simplex virus type 2 status; therefore, we were unable to allocate points for those factors. Participants were included in the analysis if they had complete data for all the other baseline factors assessed in the risk score. We calculated the HIV-1 incidence over the first year after enrollment and evaluated the predictive ability of the total score by generating receiver operating characteristic curves and calculating the area under the curve (AUC). We calculated additional performance characteristics (sensitivity and specificity) using risk score cut-points that corresponded to an HIV incidence of approximately ≥3% per year. Our primary analysis included all enrolled women; however, because the intervention significantly reduced HIV-1 incidence compared with the placebo arm, we conducted a sensitivity analysis repeating risk score evaluation stratified by the study arm. Additional exploratory analyses were performed restricted to women enrolled in South Africa because South Africa contributed the largest proportion of participants to the study. All analyses were conducted using Stata v14.2 (StataCorp, College Station, TX).

Among 2629 women enrolled in ASPIRE, 2539 had complete data at baseline for factors included in the risk score. The majority of women (58%) were not married; 39% were younger than 25 years; 21% reported that their partner had other partners; and 57% did not know if their partner had other partners; 12% reported any alcohol use in the past 3 months; 21% had a curable STI detected at baseline; and 54% were from South Africa. There were 95 seroconversions during the first year of follow-up [2566 person-years of follow-up; HIV-1 incidence = 3.70%; 95% confidence interval (CI): 3.03 to 4.52]. HIV-1 incidence was highest in South Africa (5.40%), followed by Malawi (2.61%), Uganda (1.59%), and Zimbabwe (1.48%). The HIV-1 incidence by risk score value is presented in Figure 1. The AUC was 0.69 (95% CI: 0.64 to 0.74) indicating modest predictive ability. There were no infections among women with risk scores below 2 (7% of women), and women with a score of 2 had an incidence <2% per year. Sixty-five percent of women had a risk score of ≥3, and the HIV-1 incidence among women in this category was 5.21% (95% CI: 4.22 to 6.44) compared with 0.98% (95% CI: 0.51 to 1.88) among women with a risk score <3. Using a cutoff of ≥3, risk score sensitivity and specificity were 91% and 36%, respectively. Results were similar when the risk score was separately evaluated by study arm (data not shown). Exploratory analyses restricted to women enrolled in South Africa showed similar predictive performance of the overall score, with age <25 years, being unmarried, and having a curable STI at baseline being the strongest predictors of HIV-1 acquisition within the adapted score.

FIGURE 1

FIGURE 1

An adaption of the VOICE risk score had modest performance in predicting HIV acquisition among women participating in ASPIRE. Consistent with previous applications of the risk score among women from other HIV-1 prevention trials,2 having a score ≥3 in this simplified scoring tool correlated with HIV incidence >3%, highlighting the utility of the risk score in different populations of women at risk of acquiring HIV-1. Recent World Health Organization guidelines recommend that oral PrEP should be offered as part of combination HIV-1 prevention as an additional prevention choice for individuals at substantial risk of HIV-1 infection, where “substantial risk” is defined as populations with an HIV-1 incidence >3% per year.2 As countries in Eastern and Southern Africa continue to scale-up access to oral PrEP, risk scoring tools could be used to improve efficiency in identifying women who will benefit most from priority access to PrEP and other novel HIV-1 prevention interventions, such as the dapivirine vaginal ring.10–12 For example, even among the very high-risk population participating in ASPIRE, the annual HIV-1 incidence was zero among the 7% of women with the lowest risk scores, and an additional 28% with scores of 2 had an incidence <2% per year.

Our findings should be interpreted in the context of several limitations. First, we were unable to fully assess performance of the complete VOICE risk score, as several factors were not assessed in ASPIRE. However, using the subset of factors that were assessed, risk score performance was similar in ASPIRE (AUC = 0.69) as compared to VOICE (AUC = 0.69), HPTN 035 (AUC = 0.70), and FEM-PrEP (AUC = 0.58).7 Both VOICE and ASPIRE did not include large numbers of adolescents (in ASPIRE, only 19% of participants were aged between 18 and 21 years); therefore, the performance of the risk score in this population could be limited. There may be other factors that are important to consider in assessing HIV-1 risk among adolescents, and additional work to identify such factors is paramount for efficient implementation of HIV-1 prevention interventions in this high-risk population. In addition, few women enrolled in VOICE or ASPIRE reported transactional sex or use of injection drugs. Women who engage in transactional sex or who inject drugs are already considered to be at high risk; thus, use of the VOICE risk score in these populations would likely not provide any additional benefit.

An adaptation of the VOICE risk score predicted HIV-1 acquisition over 1 year among women participating in ASPIRE. Our findings demonstrate the robustness of our risk scoring tool and the consistency of external validation results. The VOICE risk score should further be considered as a tool to inform scale-up of HIV-1 prevention strategies for women living in Eastern and Southern Africa to identify those with an anticipated HIV-1 incidence of >3%, which represents a priority group for access to PrEP and other HIV-1 prevention interventions.

Back to Top | Article Outline

ACKNOWLEDGMENTS

The authors gratefully acknowledge the contributions of the women who participated in MTN-020/ASPIRE, MTN-003/VOICE, HPTN 035, and FEM-PrEP. The authors express their sincere appreciation to the study teams for their dedicated work on data and sample collection and to the MTN Statistical and Data Management Center for their work on data management for VOICE and HPTN 035 and FHI 360 for their work on FEM-PrEP. The dapivirine vaginal ring, which was evaluated in the ASPIRE trial, was developed by the International Partnership for Microbicides.

Back to Top | Article Outline

REFERENCES

1. UNAIDS. The Gap Report. Geneva, Switzerland: WHO. Available at: http://http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf. Accessed August 17, 2015.
2. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection; 2016.
3. Kahle E, Hughes J, Lingappa J, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr. 2013;62:339–347.
4. Smith DK, Pals SL, Herbst JH, et al. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2012;60:421–427.
5. Menza TW, Hughes JP, Celum CL, et al. Prediction of HIV acquisition among men who have sex with men. Sex Transm Dis. 2009;36:547–555.
6. CDC. Pre-exposure prophylaxis for the prevention of HIV infection in the United States—2014; Clinical providers' supplement. Available at: http://http://www.cdc.gov/hiv/pdf/prepprovidersupplement2014.pdf. Accessed July 10, 2015.
7. Balkus JE, Brown E, Palanee T, et al. An empiric HIV risk scoring tool to predict HIV-1 acquisition in African women. J Acquir Immune Defic Syndr. 2016;72:333–343.
8. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–518.
9. Bekker LG, Rebe K, Venter F, et al. Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection. South Afr J HIV Med. 2016;17:1–11.
10. Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121–2132.
11. Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133–2143.
12. HIV Prevention Trials Network; HPTN 082: Evaluation of Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study; 2016. Available at: https://http://www.hptn.org/sites/default/files/2016-05/HPTN082_FINAL_Protocol_12082015_0.pdf. Accessed January 12, 2017.
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.